Tag: joint

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

(Oslo, 22. juli 2025) – Statkraft leverte sterkt driftsresultat i andre kvartal 2025, tross lavere priser, spesielt i de nordlige prisområdene i Norge og Sverige. Resultatet ble negativt påvirket av nedskrivninger, hovedsakelig på grunn av forventinger om lavere kraftpriser i enkelte regioner, samt valutaeffekter. Statkraft refokuserer for fortsatt lønnsom vekst.

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

Attachment

VANCOUVER, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) -- ERAG Energie & Rohstoff AG PCC (the “Acquiror), a private investment a private investment holding company incorporated in Liechtenstein, announces that on July 17, 2025, the Acquiror, along with two joint actors HMS Bergbau AG (“HMS”) and LaVo Verwaltungsgesellschaft MBH (“LaVo”), acquired Common Shares of Belmont Resources Inc. (TSX-V: BEA) (the “Issuer”). The Issuer completed a private placement of Common Shares, issuing a total of 26,300,00 shares at a price of $0.045 per share for proceeds of $1,183,500 (the “Private Placement”). Under the Private Placement, the Acquiror purchased 4,000,000 Common Shares, HMS purchased 15,000,000 Common Shares and LaVo purchased 7,300,000 Common Shares.

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.